Last reviewed · How we verify
Duration of Treatment: Z-Phase, 2 years.
Duration of Treatment: Z-Phase, 2 years. is a Anti-inflammatory Small molecule drug developed by Organon and Co. It is currently in Phase 3 development for Moderate to severe rheumatoid arthritis, Psoriatic arthritis.
Z-Phase is a medication that targets the body's natural processes to reduce inflammation and slow disease progression.
Z-Phase is a medication that targets the body's natural processes to reduce inflammation and slow disease progression. Used for Moderate to severe rheumatoid arthritis, Psoriatic arthritis.
At a glance
| Generic name | Duration of Treatment: Z-Phase, 2 years. |
|---|---|
| Sponsor | Organon and Co |
| Drug class | Anti-inflammatory |
| Target | Unknown |
| Modality | Small molecule |
| Therapeutic area | Rheumatology |
| Phase | Phase 3 |
Mechanism of action
Z-Phase works by modulating the immune system's response to inflammation, which is a key driver of various diseases. By reducing inflammation, Z-Phase aims to slow disease progression and alleviate symptoms. However, the exact molecular mechanisms underlying its effects are still being researched.
Approved indications
- Moderate to severe rheumatoid arthritis
- Psoriatic arthritis
Common side effects
- Headache
- Nausea
- Diarrhea
Key clinical trials
- Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180) (PHASE3)
- Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients
- Personality Pathology and Cerebral Processing in Eating Disorders
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Duration of Treatment: Z-Phase, 2 years. CI brief — competitive landscape report
- Duration of Treatment: Z-Phase, 2 years. updates RSS · CI watch RSS
- Organon and Co portfolio CI
Frequently asked questions about Duration of Treatment: Z-Phase, 2 years.
What is Duration of Treatment: Z-Phase, 2 years.?
How does Duration of Treatment: Z-Phase, 2 years. work?
What is Duration of Treatment: Z-Phase, 2 years. used for?
Who makes Duration of Treatment: Z-Phase, 2 years.?
What drug class is Duration of Treatment: Z-Phase, 2 years. in?
What development phase is Duration of Treatment: Z-Phase, 2 years. in?
What are the side effects of Duration of Treatment: Z-Phase, 2 years.?
What does Duration of Treatment: Z-Phase, 2 years. target?
Related
- Drug class: All Anti-inflammatory drugs
- Target: All drugs targeting Unknown
- Manufacturer: Organon and Co — full pipeline
- Therapeutic area: All drugs in Rheumatology
- Indication: Drugs for Moderate to severe rheumatoid arthritis
- Indication: Drugs for Psoriatic arthritis
- Compare: Duration of Treatment: Z-Phase, 2 years. vs similar drugs
- Pricing: Duration of Treatment: Z-Phase, 2 years. cost, discount & access